Abstract
Voltage-gated calcium channels are key sources of calcium entry into the cytosol. Mutations in calcium channels have been implicated in numerous disorders such as migraine, incomplete congenital X-linked stationary night blindness, epilepsy, and ataxia, and they are important therapeutic targets for the treatment of pain, stroke, hypertension, and epilepsy. Calcium channel antagonists can be broadly classified into three groups. 1) Inorganic ions typically nonselectively block the pore of most calcium channel subtypes, and in some cases, alter gating kinetics. 2) Peptides isolated from arachnids, cone snails, and snakes frequently selectively antagonize individual calcium channel subtypes by direct occlusion of the pore or altering gating kinetics. 3) Small organic molecules of various structure-activityrelationship (SAR) classes can mediate both selective and nonselective effects on individual calcium channel subtypes, and occlude the pore or reduce channel availability. Here, we provide an overview of classes of inhibitors of non-L-type calcium channels.
Keywords: calcium channels, pharmacology, conotoxin, agatoxin, high voltage activated, low voltage activated
Current Pharmaceutical Design
Title: Molecular Pharmacology of Non-L-type Calcium Channels
Volume: 11 Issue: 15
Author(s): Clinton J. Doering and Gerald W. Zamponi
Affiliation:
Keywords: calcium channels, pharmacology, conotoxin, agatoxin, high voltage activated, low voltage activated
Abstract: Voltage-gated calcium channels are key sources of calcium entry into the cytosol. Mutations in calcium channels have been implicated in numerous disorders such as migraine, incomplete congenital X-linked stationary night blindness, epilepsy, and ataxia, and they are important therapeutic targets for the treatment of pain, stroke, hypertension, and epilepsy. Calcium channel antagonists can be broadly classified into three groups. 1) Inorganic ions typically nonselectively block the pore of most calcium channel subtypes, and in some cases, alter gating kinetics. 2) Peptides isolated from arachnids, cone snails, and snakes frequently selectively antagonize individual calcium channel subtypes by direct occlusion of the pore or altering gating kinetics. 3) Small organic molecules of various structure-activityrelationship (SAR) classes can mediate both selective and nonselective effects on individual calcium channel subtypes, and occlude the pore or reduce channel availability. Here, we provide an overview of classes of inhibitors of non-L-type calcium channels.
Export Options
About this article
Cite this article as:
Doering J. Clinton and Zamponi W. Gerald, Molecular Pharmacology of Non-L-type Calcium Channels, Current Pharmaceutical Design 2005; 11 (15) . https://dx.doi.org/10.2174/1381612054021042
DOI https://dx.doi.org/10.2174/1381612054021042 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Imidazoline Receptors, Novel Agents and Therapeutic Potential
Cardiovascular & Hematological Agents in Medicinal Chemistry Astrocyte-Microglia Cooperation in the Expression of a Pro-Inflammatory Phenotype
CNS & Neurological Disorders - Drug Targets Nicotinic Acetylcholine Receptors and Epilepsy
Current Drug Targets - CNS & Neurological Disorders Ketogenic Diet Acts on Body Remodeling and MicroRNAs Expression Profile
MicroRNA The Yin and Yang of BK Channels in Epilepsy
CNS & Neurological Disorders - Drug Targets Cefepime-Induced Neurotoxicity
Central Nervous System Agents in Medicinal Chemistry 1,2,4-Triazole Derivatives as Potential Scaffold for Anticonvulsant Activity
Central Nervous System Agents in Medicinal Chemistry The Validity of Mobile Applications to Facilitate Patient Care Provided to Cancer Patients: Opportunities and Limitations
Recent Patents on Anti-Cancer Drug Discovery Longitudinal Functional MRI of Motor and Cognitive Recovery Following Stroke: A Review
Current Medical Imaging Current Development in Encapsulated Cell Therapy for Degenerative Retinopathies
Current Tissue Engineering (Discontinued) Neonatal Atlas Templates for the Study of Brain Development Using Magnetic Resonance Images
Current Medical Imaging Osteoporotic Fracture Healing: Potential Use of Medicinal Plants from the Tropics
Current Drug Targets Classical Neurotransmitters and Neuropeptides Involved in Major Depression in a Multi-neurotransmitter System: A Focus on Antidepressant Drugs
Current Medicinal Chemistry Vagus nerve stimulation in treating depression: A tale of two stories.
Current Molecular Medicine Preface:
Current Topics in Medicinal Chemistry Safety Profile of the Newest Antiepileptic Drugs: A Curated Literature Review
Current Pharmaceutical Design Glutamate Transporter 1: Target for the Treatment of Alcohol Dependence
Current Medicinal Chemistry Melatonin in the Biliary Tract and Liver: Health Implications
Current Pharmaceutical Design What have Genetically Engineered Mice Taught Us About Ischemic Injury?
Current Molecular Medicine GABAergic Modulation in Diabetic Encephalopathy-Related Depression
Current Pharmaceutical Design